AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02589145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 60 mg/m2 by vein on days -3 and -2.
Study NCT02589145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients with CD20+ tumors receive Rituximab 375 mg/m2 by vein on day -9 in the AM as an inpatient.
Study NCT02589145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8 mg by vein twice a day from Day -8 AM to Day -2 PM.
Study NCT02589145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caphosol
Description: Caphosol oral rinses 30 mL four times a day used from Day -8.
Study NCT02589145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
Study NCT02589145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Description: 100 mg by vein or mouth three times a day from Day -1
Study NCT02589145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: 40 mg subcutaneously daily from admission until platelet count drops below 50,000/mm3.
Study NCT02589145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Stem cell transplant performed on Day 0.
Study NCT02589145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Palifermin per departmental standard of care with 3 doses to be administered prior to starting chemotherapy and 3 doses starting on day 0.
Study NCT02731300 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: brain stimulation by cathodal electrode at motor cortex
Study NCT02731300 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: brain stimulation by cathodal electrode at motor cortex
Study NCT00768690 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ABT-333
Description: Capsule, or powder drug substance from the capsule powder mixed in an alternate vehicle. For additional information refer to arm description.
Study NCT01896427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 21-benzyloxy-9alpha-fluoro-16alpha-methylpregna-1,4-dien-11beta,17alpha-diol-3,20-dione
Description: single dose of dexamethasone (8mg) will injected
Study NCT01933243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: Participants will take 4 capsules daily
Study NCT01933243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Participants will take 4 capsules daily
Study NCT01868932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypertonic saline
Description: inhaled nebulized 3%NaCl
Study NCT01868932 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: inhaled nebulized 0.9% NaCl
Study NCT03237442 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cells
Description: human UC-MSCs: 0.2ml(about 2\*10\^6 cells) subconjunctival injection
Study NCT03237442 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Saline injection
Study NCT00449605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Tablet, oral administration
Study NCT00449605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Tablet, oral administration
Study NCT00449605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin continued at stable dose as background therapy
Study NCT00449605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin continued at stable dose as background therapy
Study NCT02580929 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy before surgery
Study NCT04776642 — intervention group
Intervention type: OTHER
Intervention: Biobank for Left atrial appendage tissue
Description: Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
Study NCT04776642 — intervention group
Intervention type: OTHER
Intervention: Biobank for Blood
Description: Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
Study NCT00768690 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ketoconazole
Description: Tablet, see arms for intervention description
Study NCT00768690 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: Capsule or powder drug substance from the capsule powder mixed in an alternative vehicle. For additional information refer to arm description.
Study NCT04776642 — intervention group
Intervention type: OTHER
Intervention: Biobank for One or more of following fat patches: epicardial fat, subcutaneous fat, pericardial fat, visceral fat.
Description: Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
Study NCT02056353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LOGIC-Insulin algorithm
Study NCT02056353 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paper protocol
Study NCT01660386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 100mg po once
Study NCT01660386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: 5mg po once
Study NCT01660386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: 2mg po once
Study NCT01660386 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Blank control
Description: the subjects take no medication at experimental day and start bi-phase hyperglycaemic clamp at 9am.
Study NCT00412412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNF2024
Description: Oral doses of CNF2024 as specified in the protocol.
Study NCT00412412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNF2024 + trastuzumab
Description: Oral doses of CNF2024 as specified in the protocol Intravenous doses of trastuzumab as specified in the package insert.
Study NCT00349934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMP321
Description: This study is an open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory setting with patients receiving as a first line chemotherapy for metastatic breast carcinoma the standard 6 cycles of paclitaxel (80 mg/m² at D1, D8 and D15 of every 4-week cycle).~Three IMP321 dose levels (250 µg, 1,250 µg and 6,250 µg) will be evaluated in three cohorts of 8 patients. At any given dose level the patients will be administered one dose every two weeks for a total of 24 weeks (12 s.c. injections in total), separated by 13-day intervals free of IMP321 administration.~The repeated single doses will be administered on D2 and D16 of the 4-week cycles, on the day which follows chemotherapy.
Study NCT01071655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX
Description: BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1~BVZ + XELIRI. Bevacizumab 7,5 mg/kg day 1; Capecitabine 800 mg/m2/12 h days 1-14; Irinotecan 200 mg/m2 day 1~BVZ + FUIRI. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Irinotecan 80 mg/m2 weekly~BVZ + FUOX. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Oxaliplatin 85 mg/m2 biweekly
Study NCT01071655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BVZ+XELOX
Description: BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1
Study NCT01144052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon beta-1b
Description: Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 month at study entry. After a wash-out period of one month, interferon-beta-1b will be administered subcutaneously every other day as indicated by the manufacturers' instructions including the stepwise up-titration scheme as recommended for treatment start. The final dose of interferon beta-1b is 250 mcg (8 million International Units \[MIU\])
Study NCT01144052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natalizumab
Description: Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.
Study NCT01576380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Description: TKI258 is dosed on a flat scale of 500 mg, to be administered orally on a 5 days on / 2 days off dosing schedule which will be repeated every week.
Study NCT03454841 — intervention group
Intervention type: DRUG
Intervention: Prasugrel
Description: Patients with myocardial infarction will receive a 60 mg prasugrel loading dose, followed by a maintenance dose of 10 mg once daily
Study NCT03454841 — intervention group
Intervention type: DRUG
Intervention: Ticagrelor
Description: Patients with myocardial infarction will receive a 180 mg ticagrelor loading dose, followed by a maintenance dose of 90 mg twice daily
Study NCT01534065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Barricaid
Description: Implanted intra-operatively during discectomy
Study NCT00733876 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multipotent Stromal Cells
Description: Post-operative administration of MSC
Study NCT00733876 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Administration of MSC
Description: Dose escalation protocol
Study NCT03098563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinded study medication
Description: Blinded study medication: This is a double-blind within-subject Phase II trial. Study medications will remain blinded. Participants may receive a dose of medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications or placebo (sugar pill). All subjects will serve as their own control. Study medication administration will be randomized within each participant.
Study NCT02383940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sotagliflozin 400 mg, once daily before the first meal of the day
Study NCT02383940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily before the first meal of the day
Study NCT00685698 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TG-873870 (Nemonoxacin)
Description: 750 mg
Study NCT04239469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KL16-012
Description: Standardized cannabis sativa extract of THC and CBD, with each drop containing 1 mg of THC and 0.45 mg of CBD
Study NCT04239469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03784001 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gratitude + No Expectations Intervention
Description: Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a short gratitude list of up to five items. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest
Study NCT03784001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude + Expectations Intervention
Description: Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a short gratitude list of up to five items. Participants will have a statement at the top of their Google form about the benefits of gratitude. Examples of these statements are: Practicing gratitude may increase social connectedness and Cultivating gratitude was shown to improve school satisfaction in a UK sample of students. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest
Study NCT03784001 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Events Control Intervention
Description: Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a list of up to five items about events from their day. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest.
Study NCT01509144 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EN41-FPA2 HIV vaccine
Description: Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)
Study NCT01509144 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EN41-FPA2 HIV vaccine
Description: Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)
Study NCT01509144 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EN41-FPA2 HIV vaccine
Description: Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)
Study NCT01509144 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EN41-FPA2 HIV vaccine
Description: Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)
Study NCT01509144 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Na Cl Placebo vaccine
Description: Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)
Study NCT03525067 — intervention group
Intervention type: OTHER
Intervention: Bile sampling for bacterial examination
Description: At the beginning of pancreaticoduodenectomy, patients had bile sampling from the gallbladder or from the common bile duct for bacterial examination and study of susceptibility to antibiotics.
Study NCT01158287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Study NCT01158287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT03570489 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Patients will bicycle for 20 minutes per day for 5 days per week for 6 months
Study NCT03570489 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Relaxation
Description: Patients will listen to a relaxation tape 20 minutes per day 5 Days a week for 6 months
Study NCT03245047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplement with AN 777
Description: Oral Nutritional Supplement with AN 777, 2 servings a day
Study NCT03245047 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral Nutritional Supplement
Description: Oral Nutritional Supplement, 2 servings a day
Study NCT01156376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potassium Oxalate without Fluoride
Description: 1.40% Potassium Oxalate Sensitive Mouthwash without fluoride - Rinse with 10ml for 60 seconds, four times daily successively at 1 hour intervals for five days
Study NCT01156376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potassium Oxalate with Fluoride
Description: 1.40% Potassium Oxalate Sensitive Mouthwash with fluoride - Rinse with 20ml for 60 seconds, four times daily successively at 1 hour intervals for five days
Study NCT01156376 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator PO-116-A
Description: Rinse with comparator mouthwash 20ml for 30 seconds, four times daily successively at 1 hour intervals for five days
Study NCT01170793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educative telephone coaching (ETC)
Description: a 30 to 45 minutes phone call, by appointment, by the nurse
Study NCT01390662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: one tablet of vitamin D3 70 µg pr. day, for 24 weeks.
Study NCT01390662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet of sugar pill pr. day, for 24 weeks.
Study NCT01219907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2/neu peptide vaccine
Description: Given intradermally
Study NCT01219907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT01219907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ex vivo-expanded HER2-specific T cells
Description: Given IV
Study NCT01219907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01219907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT01219907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Correlative studies
Study NCT01217853 — intervention group
Intervention type: DEVICE
Intervention: SENSIMED Triggerfish
Description: Contact lens-based device for continuous intraocular pressure monitoring
Study NCT04427943 — intervention group
Intervention type: PROCEDURE
Intervention: revision surgery
Description: The intervention is the planned revision surgery according to local guidelines.
Study NCT01506440 — intervention group
Intervention type: PROCEDURE
Intervention: cognitive assessment
Description: Given cognitive assessments
Study NCT01506440 — intervention group
Intervention type: PROCEDURE
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT03894072 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Conventional CPAP
Study NCT03894072 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFHO
Description: A device that can provide heated humidified oxygen up to 30-60 liter per minute, FiO2 (fraction of inspired oxygen) 0.21-0.95
Study NCT00821951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 200 mg, 300 mg, 400 mg, once per RT fraction
Study NCT00821951 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Standard fractionation of 3.0 Gy per day over 2 weeks, to a total dose of 30 Gy, will be utilized for all patients. All patients will be treated one time per day, 5 days per week unless interruption is clinically indicated.
Study NCT03791554 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group A (Lateral closed tunnel subepithelial CT graft)
Description: Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the adjacent teeth to treating gingival recession with edges of the recession sutured together after placing connective tissue graft
Study NCT03791554 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group B (Tunnel procedure with subepithelial CT graft)
Description: Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the prepared tunnel to treating gingival recession
Study NCT02318953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile app follow-up care
Description: The mobile app follow-up care is an application that can be loaded on to a smartphone. It allows the patient to submit photos of their surgical site, VAS pain scores, and QoR9 scores. The information collected is transmitted to members of the surgical team (i.e. the primary surgeon) and used to monitor recovery over the first 30-days following surgery.
Study NCT02318953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional, in-person follow-up care
Description: This includes a typical in-person visit with the operating surgeon at one- and four-weeks after surgery.
Study NCT05082753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin tablets (3 mg Ivermectin)
Description: Two Ivermectin tablets were administered orally.
Study NCT05082753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin tablets (3 mg Ivermectin)
Description: Two Ivermectin tablets were administered orally.
Study NCT05082753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stromectol ® tablets
Description: Two Ivermectin tablets were administered orally.
Study NCT05082753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stromectol ® tablets
Description: Two Ivermectin tablets were administered orally.
Study NCT03266926 — intervention group
Intervention type: DRUG
Intervention: Bupivacaine
Description: 0.25% Bupivacaine with epinephrine will be applied to vaginal packing that is placed post vaginal reconstruction surgery.
Study NCT03266926 — intervention group
Intervention type: DRUG
Intervention: Premarin Vaginal cream
Description: A Premarin vaginal cream will be used to coat the vaginal pack, prior to insertion in patients post vaginal reconstruction surgery.
Study NCT03841318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 36 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
Study NCT03841318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biopsy of the labial salivary gland
Description: Part of the biopsy of the labial salivary gland